Clinical trials: Nonsmall Cell Lung Cancer, Stage II
Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
This phase II Lung-MAP treatment trial tests whether carboplatin and pemetrexed with or without selpercatinib works to shrink tumors in patients with RET fusion-positive non-small cell lung cancer that is stage IV or has not…
- Conditions
- Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT05364645
- Testing
- Carboplatin, Pemetrexed, Selpercatinib
- Where
- 265 sites in United States
- Sponsor
- SWOG Cancer Research Network
Non Small Cell Lung Cancer, Stage IIIA Lung Cancer
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
This is an open-label, phase II, multi-centre clinical trial. 97 Patients with stage IIIA and IIIB non-small cell lung cancer will be enrolled.
- Conditions
- Non Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer
- Trial name
- ATHENEA (NCT07153445)
- Testing
- Atezolizumab, Paclitaxel, Carboplatin
- Where
- 21 sites in Spain
- Volunteers
- 97 people
- Sponsor
- Fundación GECP
Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study
This phase I/II trial studies the side effects of sapanisertib and nivolumab and to see how well they work in treating patients with stage I-IV non-small cell lung cancer whose disease got worse on previous PD-1/PD-L1 inhibitor…
- Conditions
- Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
- Trial name
- NCT05022394
- Testing
- Nivolumab, Sapanisertib
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Metastatic Cancer
Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00238251
- Testing
- gefitinib, temozolomide, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 59 people
- Sponsor
- Swiss Cancer Institute
Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer
Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
This is an open label, multi-institutional, single arm Phase II trial. All patients will be treated with Carboplatin, Paclitaxel, Durvalumab and Radiation.
- Trial name
- NCT03871153
- Testing
- Durvalumab, Paclitaxel, Carboplatin
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Greg Durm, MD
Non-Small Cell Lung Cancer
OSI-774 (Erlotinib, Tarceva) in Elderly Patients
The purpose of this research study is to determine if OSI-774 (Tarceva) is effective in the treatment of non-small cell lung cancer and to further study its side effects.
- Trial name
- NCT00200395
- Testing
- Tarceva
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Non-Small Cell Lung Cancer
A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)
This is a randomized, double-blind, Phase II, placebo-controlled trial adding on to a background of effective treatment designed to evaluate the efficacy, safety, and pharmacokinetics of PRO95780 combined with paclitaxel +…
- Trial name
- NCT00480831
- Testing
- bevacizumab, carboplatin, paclitaxel
- Volunteers
- 128 people
- Sponsor
- Genentech, Inc.
Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial
Non Small Cell Lung Cancer (NSCLC) represents the first cancer related cause of death worldwide with 1.4 millions of deaths every years.
- Trial name
- ONC-MANILA12 (NCT02176369)
- Testing
- Vinorelbine
- Where
- 20 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Non-small-cell Lung Cancer
Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)
The goal of this clinical research study is to compare 2 types of radiotherapy, stereotactic body photon radiotherapy (SBRT) and stereotactic body proton radiotherapy (SBPT).
- Trial name
- NCT01511081
- Testing
- SBRT (stereotactic body radiotherapy), SBPT (stereotactic body proton therapy)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have…
- Trial name
- NCT00004151
- Testing
- acridine carboxamide
- Where
- 8 sites in Austria, Denmark and 4 more
- Volunteers
- 15 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Colorectal Cancer
Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer
RATIONALE: Identification of genes that may be associated with developing certain types of cancer may someday provide important information about a person's risk of getting cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00003329
- Testing
- gene mapping
- Where
- 32 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- Eastern Cooperative Oncology Group
NSCLC
Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients
Between 10% and 25% of newly diagnosed stage IIIB/stage IV patients currently receive single agent chemotherapy regimens. A significant proportion of these patients will be elderly (70 years of age) and many oncologists would…
- Trial name
- NCT00754364
- Testing
- Pemetrexed/Carboplatin, Gemcitabine
- Where
- Italy
- Volunteers
- 108 people
- Sponsor
- Armando Santoro, MD
NSCLC, EGFR Gene Amplification
Combination of Metformin With Gefitinib to Treat NSCLC
The purpose of this study is to determine whether metformin in combination with gefitinib are effective in patients with previously untreated advanced or metastatic Non-Small-Cell Lung cancer with epidermal growth factor receptor…
- Conditions
- NSCLC, EGFR Gene Amplification, Advanced Cancer, Stage IIIB NSCLC
- Trial name
- CGMT (NCT01864681)
- Testing
- Gefitinib and Metformin
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Lung Cancer
Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy
RATIONALE: Measuring changes in glucose metabolism in patients with cancer may help doctors predict how patients respond to treatment.
- Trial name
- NCT00450567
- Testing
- computed tomography, positron emission tomography, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Non Small Cell Lung Cancer
Cellular Immunotherapy Synergize Chemotherapy in Patients With Stage IV NSCLC
This is a randomized, open-label, phaseⅡ study evaluating efficacy and safety of DC (dendritic cells) vaccine concurrent with chemotherapy compared to chemotherapy alone in patients with stage IV NSCLC (non small cell lung…
- Trial name
- NCT02669719
- Testing
- chemotherapy followed dendritic cells, pemetrexed and carboplatin
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer
Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00182806
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Roswell Park Cancer Institute
Lung Cancer
Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004126
- Testing
- oxaliplatin, paclitaxel
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of Chicago
Non-Small Cell Lung Cancer
Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
The aim of this study is to evaluate if the multi modality treatment pemetrexed combined with cisplatin and radiotherapy can lead to a better tumor control and/or a better side-effect profile in patients with locally advanced…
- Trial name
- PACCORA (NCT00497315)
- Testing
- combination chemotherapy (pemetrexed + cisplatin), thoracic irradiation + pemetrexed
- Where
- 3 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- University Hospital, Antwerp
Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage II
Dose-painting Radiation for LA-NSCLC
The study evaluated the effectiveness, safety and immune effects of dose-painting radiation in patients with locally advanced non-small cell lung cancer.
- Trial name
- DPRLC (NCT05031533)
- Testing
- Dose-Painting Radiation
- Where
- 4 sites in China
- Volunteers
- 46 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT
Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study
Lung cancer still occupies the highest incidence and mortality rate in the wordwild, and non-small cell lung cancer (NSCLC) accounts for about 80% to 85% of all lung cancers.
- Trial name
- NCT04517526
- Testing
- pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Cancer Hospital, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.